重大事件
即時報告
8-K
2026-05-21
Bicycle Therapeutics 提交 8-K 表格：ASCO 公佈膀胱癌臨床初步數據
AI 繁中摘要
📄 **Bicycle Therapeutics 提交 8-K 表格：ASCO 公佈膀胱癌臨床初步數據**
Bicycle Therapeutics plc（納斯達克代碼：BCYC）於 2026 年 5 月 21 日向美國證交會提交 8-K 申報，披露當日公司在美國臨床腫瘤學會（ASCO）年會上公佈了 Duravelo-2 研究用於轉移性尿路上皮癌（mUC）的初步數據。
🚀 **重點一覽**
- **申報類型：** 8-K（重大事件報告）
- **事件：** 發佈新聞稿，公佈 Duravelo-2 臨床試驗初步結果
- **適用症：** 轉移性尿路上皮癌（mUC）
- **會議：** 2026 年 ASCO 年會
- **公司註冊地：** 英國英格蘭及威爾斯，主要行政辦公室位於劍橋 Granta Park
**📈 對投資者的潛在意義**
此項 8-K 申報本身不包含財務業績，但 Duravelo-2 初步數據是 Bicycle Therapeutics 在腫瘤管線上的關鍵里程碑。正向數據有助於強化市場對其雙環肽技術平台（Bicycle®）的信心，可能影響股價短期表現。投資者應密切留意隨後發布的新聞稿全文，以了解具體緩解率、安全性及持續研發計劃。
**💡 小結**
Bicycle Therapeutics 透過 8-K 快速向市場通報臨床進展，符合上市公司的資訊揭露責任。建議投資者關注後續完整數據發表及公司管理層的未來展望。
展開英文正文
false 0001761612 X0 00-0000000 true 0001761612 2026-05-21 2026-05-21 0001761612 us-gaap:CommonStockMember 2026-05-21 2026-05-21 0001761612 bcyc:AmericanDepositarySharesMember 2026-05-21 2026-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2026 Date of Report (Date of earliest event reported) Bicycle Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales 001-38916 Not applicable (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge United Kingdom CB21 6GS (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: +44 1223 261503 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name of each exchange on which registered Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC* American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 8.01. Other Events On May 21, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release announcing initial Duravelo-2 data for metastatic urothelial cancer at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued May 21, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 21, 2026 BICYCLE THERAPEUTICS PLC By: /s/ Travis Thompson Name: Travis Thompson Title: Chief Financial Officer